Etanercept biosimilar (Shanghai Celgen)

依那西普生物类似药 (Shanghai Celgen)

Report date: 2025/07/31 13:30:11

Base Information

Drug NameEtanercept biosimilar (Shanghai Celgen)
Drug Alias Name强克
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionTumor necrosis factor α inhibitorsTumor necrosis factor β inhibitors
TargetsTumor necrosis factor αTumor necrosis factor β
Therapy Area/IndicationsPlaque psoriasisPsoriasisArthritis, Rheumatoid +[4] 
Global Approved IndicationsSpondylitis, Ankylosing
Approved Indications in ChinaSpondylitis, Ankylosing
Original Approved Country/TerritoryMainland China
Original Approved Date2011/04/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Celgen Bio-Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Celgen Bio-Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSpondylitis, Ankylosing
Inactive IndicationsPlaque psoriasisPsoriasisArthritis, Rheumatoid

Other Information

ATC CodeL04AB01
Related LinksN/A